Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Plasma cell 1NET 1Lymphoid 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

selinexor 2pazopanib 2Radiotherapy 2Injections 2Ifosfamide 2Filgrastim 2Doxorubicin 2Cyclophosphamide 2sargramostim 1resiquimod 1repotrectinib 1poly ICLC 1interferon-alfa-1b 1cc-486 1aldesleukin 1Voriconazole 1Thalidomide 1Suspensions 1Rituximab 1Radiation 1Quality of Life 1Proton Therapy 1Peripheral Blood Stem Cell Transplantation 1Pentetic Acid 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Minocycline 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × repotrectinib × Plasma cell × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡